CellaVision AB Cash Flow Conversion Efficiency
CellaVision AB cash flow conversion efficiency. Based on the latest financial reports, CellaVision AB (CEVI) has a cash flow conversion efficiency ratio of 0.058x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr51.43 Million ≈ $5.53 Million USD) by net assets (Skr887.58 Million ≈ $95.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CellaVision AB (2006–2025)
Cash flow conversion efficiency of CellaVision AB from 2006 to 2025. This chart illustrates how CellaVision AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CellaVision AB stock price for real-time trading data and today's change.
CellaVision AB Cash Flow Conversion Ratio Explained
CellaVision AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CellaVision AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CellaVision AB ranked by their cash flow conversion efficiency. Also see CEVI market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pony Testing International Group Co
SHE:300887
|
0.041x |
|
LightPath Technologies Inc
NASDAQ:LPTH
|
-0.060x |
|
Hangzhou Zhengqiang Corporation Limited
SHE:301119
|
0.045x |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
0.003x |
|
Amper S.A.
MC:AMP
|
-0.602x |
|
CREDIT CORP. GROUP LTD.
F:2RC
|
N/A |
|
IntelliEPI Cayman
TWO:4971
|
0.015x |
|
Qinghai Huzhu Barley Wine Co Ltd
SHE:002646
|
0.000x |
Annual Cash Flow Conversion Efficiency for CellaVision AB (2006–2025)
The table below shows the annual cash flow conversion efficiency of CellaVision AB from 2006 to 2025. Review CEVI free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr887.58 Million ≈ $95.52 Million |
Skr200.53 Million ≈ $21.58 Million |
0.226x | -7.13% |
| 2024-12-31 | Skr815.73 Million ≈ $87.79 Million |
Skr198.44 Million ≈ $21.36 Million |
0.243x | -11.28% |
| 2023-12-31 | Skr716.39 Million ≈ $77.09 Million |
Skr196.44 Million ≈ $21.14 Million |
0.274x | +28.15% |
| 2022-12-31 | Skr641.63 Million ≈ $69.05 Million |
Skr137.28 Million ≈ $14.77 Million |
0.214x | -27.22% |
| 2021-12-31 | Skr543.28 Million ≈ $58.47 Million |
Skr159.72 Million ≈ $17.19 Million |
0.294x | +77.58% |
| 2020-12-31 | Skr429.62 Million ≈ $46.23 Million |
Skr71.12 Million ≈ $7.65 Million |
0.166x | -54.22% |
| 2019-12-31 | Skr348.37 Million ≈ $37.49 Million |
Skr125.99 Million ≈ $13.56 Million |
0.362x | +41.78% |
| 2018-12-31 | Skr290.38 Million ≈ $31.25 Million |
Skr74.07 Million ≈ $7.97 Million |
0.255x | -30.10% |
| 2017-12-31 | Skr240.85 Million ≈ $25.92 Million |
Skr87.90 Million ≈ $9.46 Million |
0.365x | -1.73% |
| 2016-12-31 | Skr206.18 Million ≈ $22.19 Million |
Skr76.57 Million ≈ $8.24 Million |
0.371x | -22.55% |
| 2015-12-31 | Skr183.52 Million ≈ $19.75 Million |
Skr88.00 Million ≈ $9.47 Million |
0.480x | +82.35% |
| 2014-12-31 | Skr151.30 Million ≈ $16.28 Million |
Skr39.78 Million ≈ $4.28 Million |
0.263x | +27.77% |
| 2013-12-31 | Skr132.52 Million ≈ $14.26 Million |
Skr27.27 Million ≈ $2.93 Million |
0.206x | +123.68% |
| 2012-12-31 | Skr124.91 Million ≈ $13.44 Million |
Skr11.49 Million ≈ $1.24 Million |
0.092x | -63.77% |
| 2011-12-31 | Skr126.07 Million ≈ $13.57 Million |
Skr32.02 Million ≈ $3.45 Million |
0.254x | +151.39% |
| 2010-12-31 | Skr113.42 Million ≈ $12.21 Million |
Skr11.46 Million ≈ $1.23 Million |
0.101x | -63.28% |
| 2009-12-31 | Skr74.80 Million ≈ $8.05 Million |
Skr20.58 Million ≈ $2.21 Million |
0.275x | +896.24% |
| 2008-12-31 | Skr45.98 Million ≈ $4.95 Million |
Skr1.27 Million ≈ $136.67K |
0.028x | -91.68% |
| 2007-12-31 | Skr20.07 Million ≈ $2.16 Million |
Skr6.67 Million ≈ $717.37K |
0.332x | +519.92% |
| 2006-12-31 | Skr17.73 Million ≈ $1.91 Million |
Skr950.00K ≈ $102.24K |
0.054x | -- |
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more